VolitionRx reports Q2 revenue $400K, consensus $375.72K

Q2 net loss was down 11% vs. the prior year. CEO Cameron Reynolds says, “2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q platform in the human diagnostics market and as reported previously we are in confidential discussions with more than ten companies. We are at various stages of the process across our different pillars ranging from due diligence, to tech transfer, to evaluation of clinical samples, to term sheet negotiation, and contract finalization. I am delighted to see things moving through the funnel, albeit confidentially at this stage, and expect to be able to sign our first agreement in the human diagnostics space this quarter. We believe that our strong clinical evidence supports the broad applicability of our Nu.Q technology in critical areas such as cancer and sepsis, including as a biomarker of interest to epigenetic drug development, an ever expanding area of focus for big pharma. Our goal is to secure multiple licensing agreements in the human diagnostics space this year, mirroring our successful strategy in the veterinary market. Similar to the veterinary market, we anticipate diverse deal structures, with potential for up front and milestone payments, and future recurring revenue. Overall, we are making strong progress and expect the first human out licensing deal this quarter.”